Welcome to our dedicated page for Inmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on Inmune Bio stock.
INmune Bio Inc. develops clinical-stage immunology and biotechnology treatments designed to target the innate immune system in disease. Company news commonly centers on three platforms: CORDStrom, a pooled allogeneic human umbilical cord-derived mesenchymal stromal/stem cell platform; XPro, a dominant-negative TNF platform intended to selectively neutralize soluble TNF; and INKmune, a cell-based medicine designed to prime natural killer cells against residual cancer.
Recurring updates include clinical and preclinical data, regulatory pathway discussions, manufacturing and collaboration agreements, conference presentations, shareholder communications, and quarterly or annual financial results. Coverage also reflects program areas such as recessive dystrophic epidermolysis bullosa, early Alzheimer’s disease, neuroinflammation, inflammatory disease and oncology.
INmune Bio Inc. (NASDAQ: INMB) announced results from an additional analysis of blinded data from its AD02 Phase II Alzheimer's Disease trial. The analysis showed exceptional performance of the novel cognitive measure EMACC and a highly significant correlation between EMACC and the Clinical Dementia Rating-Sum of Boxes (CDR-SB). Key findings include:
1. A highly significant correlation (p0.001) between baseline scores on EMACC and CDR-SB.3. EMACC's ability to differentiate between disease stages with an effect size of 0.87 (p.0001).The company believes these results validate their trial design and endpoint selection, potentially de-risking their clinical program compared to traditional AD drug development approaches.
INmune Bio Inc. (Nasdaq: INMB) has announced a $13.0 million registered direct offering of common stock and warrants. The company will sell 2,341,260 shares of common stock and warrants to purchase an additional 2,341,260 shares. The combined purchase price is $5.50 per share and warrant for institutional investors and $6.50 for company insiders. Warrants will be exercisable after six months at $6.40 per share with a five-year expiration. The offering is expected to close around September 16, 2024. Proceeds will be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for this offering, which is made pursuant to an effective shelf registration statement.
INmune Bio Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, has announced its participation in the Baird 2024 Global Healthcare Conference in New York, NY. The company's management will present on Tuesday, September 10, 2024, from 8:30-9:00 AM Eastern Time in Session III, Empire Ballroom B, Mezzanine Level.
INmune Bio focuses on developing treatments that harness a patient's innate immune system to fight disease. This conference presentation provides an opportunity for the company to showcase its progress and engage with investors in the healthcare sector. The Baird Global Healthcare Conference is a significant event that brings together industry leaders and investors to discuss advancements in healthcare.
INmune Bio Inc. (NASDAQ: INMB) announced Q2 2024 results and provided a business update. Key highlights include:
1. The Phase 2 trial for XPro™ in Early Alzheimer's Disease is on track to complete enrollment by Q3 end.
2. A new Phase 1b analysis shows XPro's™ significant effects on synaptic proteins.
3. INKmune™ platform progress includes a new formulation and completion of the first cohort in the Phase I/II trial for metastatic castration-resistant prostate cancer.
4. The company raised $14.5 million in equity capital.
5. Q2 2024 financial results: Net loss of $9.7 million, R&D expenses of $7.1 million, and cash position of $31.1 million as of June 30, 2024.
INmune Bio (NASDAQ: INMB) presented new Phase 1 study data at the Alzheimer's Association International Conference, demonstrating XPro's™ dose-dependent effect on synaptic proteins in Alzheimer's patients. The 12-week treatment resulted in significant changes to proteins essential for neuron communication. This aligns with preclinical models and supports the restoration of normal immune function.
The company's VP of Neuroscience, CJ Barnum, emphasized the importance of these findings, as synaptic loss is an early and devastating consequence of Alzheimer's. CEO RJ Tesi highlighted that this cellular-level evidence supports recent EEG data showing improved synaptic function. INmune Bio is currently conducting a Phase 2 trial for mild to moderate Alzheimer's, with top-line results expected in early 2025.
INmune Bio Inc. (NASDAQ: INMB), a clinical-stage immunology company, has announced its upcoming second quarter 2024 financial results and corporate update conference call. The event is scheduled for Thursday, August 1, 2024, at 4:30 PM EDT. Investors and interested parties can participate via phone or live audio webcast. The call will cover results for the quarter ended June 30, 2024, and provide insights into the company's current operations and future plans. A replay of the call will be available until August 8, 2024, and a transcript will be provided approximately 24 hours after the scheduled call.
INmune Bio Inc. (NASDAQ: INMB) has published a landmark paper in the Journal for ImmunoTherapy of Cancer, detailing the biology of their Natural Killer cancer immunotherapy, INKmune™. The study demonstrates that memory-like natural killer (mlNK) cells, generated by either cytokine or INKmune™ priming, show increased cytotoxicity against multiple tumor types. Notably, mlNK cells from cancer patients are as potent as those from healthy volunteers, supporting INKmune's in vivo treatment approach.
The research provides insights into NK cell memory mechanisms, potentially leading to innovative treatments for hematological malignancies and solid tumors. INKmune™ priming increases proteins that protect NK cells in the tumor microenvironment, which is promising for their ongoing clinical trial in metastatic castration-resistant prostate cancer. The study also demonstrates in vivo generation of mlNK cells and their enhanced metabolic function, suggesting improved performance in the tumor microenvironment.
INmune Bio (NASDAQ: INMB) has completed a blinded interim analysis of its Phase II Alzheimer’s Disease (AD) trial, AD02. The trial uses the Early Mild Alzheimer’s Cognitive Composite (EMACC) as its primary endpoint. The analysis, conducted by third-party statisticians and neuropsychologists, confirmed the trial’s design, operational execution, and data management are of high quality. The interim results showed no need to change the trial design or sample size, reinforcing the EMACC's suitability in measuring cognitive changes in early AD. EMACC was chosen for its objective and validated cognitive measures, previously demonstrated in Biogen studies, and its strong association with biological markers of inflammation. Dr. CJ Barnum, VP of Neuroscience, endorsed the positive findings, along with consultants Dr. Paul Maruff and Dr. Judith Jaeger, citing the EMACC’s high acceptability and reliability in detecting cognitive changes in patients with early AD.
INmune Bio (NASDAQ: INMB), a clinical-stage inflammation and immunology company, will join the Russell 3000® Index following the 2024 Russell US Indexes annual reconstitution. Effective July 1, the inclusion is based on market capitalization rankings as of April 30. This membership also means automatic inclusion in either the Russell 1000® or Russell 2000® Index, and relevant growth and value style indexes, lasting one year. CEO Dr. Raymond J. Tesi believes this will boost the company's visibility and attract more investors. The Russell indexes, used by investment managers for benchmark strategies, reflect $10.5 trillion in assets.
INmune Bio Inc. announced its first-quarter 2024 financial results and provided a business update, highlighting milestones in their DN-TNF, INB03 cancer, and INKmune platforms. The company raised $14.5 million in equity capital, completed the first dosing in a Phase I/II trial of INKmune for mCRPC, and disclosed a net loss of $11.0 million for the quarter ended March 31, 2024.